Join or Renew Your Membership Join

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Impact of Viz.ai and RapidAI on Thrombectomy Times in Large Telemedicine System
Cerebrovascular Disease and Interventional Neurology
P1 - Poster Session 1 (8:00 AM-9:00 AM)
5-025

The utilization of artificial intelligence (AI) platforms to provide rapid access to images, LVO detection, and team communication in acute stroke protocols is expanding globally. There is evidence from small studies that they enhance care, but minimal evidence from large trials directly comparing stroke workflow metrics of these platforms.

Compare the arrival to Neurointerventionalist (NIR) Notification times for facilities utilizing Viz.ai, RapidAI, and no AI software for acute stroke.

Acute stroke consultations seen in the emergency department in 227 facilities (27 states) from July 1, 2021 to December 31, 2021 were extracted from the TeleCare by TeleSpecialistsTM database. The encounters were reviewed for demographics, LVO, accepted for intervention, arrival to NIR notification time, and AI software used. Patients were classified into three groups based on use of Viz.ai, RapidAI or no AI software. The median arrival to NIR notification times were compared.

A total of 25,430 patients were included: No AI group (7,433), RapidAI (6,726), and Viz.ai (11,271). The median arrival to NIR notification time for No AI was 89 minutes when compared to RAPIDAI 58 minutes and Viz.ai 54 minutes was significantly longer, p <0.0001. There was no significant difference when RapidAI and Viz.ai were directly compared. More advanced imaging was performed and LVOs detected with AI software platforms when compared to No AI. RapidAI had a higher rate of advanced imaging performed and more LVOs found than Viz.ai.

Utilization of an AI platform showed earlier notification of NIR by more than 30 minutes in this large multi-state telestroke system. No significant difference was seen between platforms for time to NIR notification. Since the utilization of either AI platform had such a profound impact, this is strong evidence to recommend utilization of an AI platform at all stroke centers.
Authors/Disclosures
Theresa B. Sevilis, DO, FAAN (Telespecialists, LLC)
PRESENTER 		Dr. Sevilis has stock in Moderna.
Mariecken V. Fowler, MD, FAAN (MV Fowler MD PLLC) Dr. Fowler has nothing to disclose.
Amanda Avila, MD Dr. Avila has nothing to disclose.
Caitlyn Boyd (TeleSpecialists) No disclosure on file
Lan Gao (University of Tennessee) No disclosure on file
Oleg Collins (TeleSpecialists) No disclosure on file
Thomas G. Devlin, MD, PhD (Memorial Hospital) Dr. Devlin has received personal compensation for serving as an employee of Neuroscience Innovation Foundation. Dr. Devlin has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Nova Signal. Dr. Devlin has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Viz.ai. Dr. Devlin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medtronic. Dr. Devlin has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Medtronic. Dr. Devlin has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Viz,ai. Dr. Devlin has received personal compensation in the range of $5,000-$9,999 for serving as an officer or member of the Board of Directors for Neuroscience Innovation Foundation. Dr. Devlin has stock in Nova Signal. Dr. Devlin has stock in Viz.ai. The institution of Dr. Devlin has received research support from Viz.ai. Dr. Devlin has received research support from Nova Signal. Dr. Devlin has received intellectual property interests from a discovery or technology relating to health care.